Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy
LXEO•FDA grants RMAT designation for LX2020
Lexeo Therapeutics won FDA RMAT designation for LX2020, an AAV gene therapy for PKP2-associated arrhythmogenic cardiomyopathy.
Designation was supported by interim data from the ongoing Phase I/II HEROIC-PKP2 trial.
LX2020 also holds FDA Orphan Drug and Fast Track designations, supporting an expedited development path.
